Bio-Rad Laboratories Inc. Class A

799.42+13.78+1.75%Vol 56.84K1Y Perf 56.12%
Sep 23rd, 2021 13:24 DELAYED
BID798.66 ASK799.69
Open790.22 Previous Close785.64
Pre-Market792.55 After-Market-
 6.91 0.88%  - -
Target Price
843.33 
Analyst Rating
Strong Buy 1.00
Potential %
5.55 
Finscreener Ranking
★★★★★     62.47
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     65.53
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     74.95
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
90.27 
Earnings Rating
Strong Buy
Market Cap23.80B 
Earnings Date
4th Nov 2021
Alpha0.02 Standard Deviation0.08
Beta0.85 

Today's Price Range

786.81799.98

52W Range

490.73832.70

5 Year PE Ratio Range

5.30288.30

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
0.05%
1 Month
0.35%
3 Months
25.53%
6 Months
37.59%
1 Year
56.12%
3 Years
163.20%
5 Years
386.95%
10 Years
771.09%

TickerPriceChg.Chg.%
BIO799.4213.78001.75
AAPL146.871.02000.70
GOOG2 840.6021.83000.77
MSFT299.951.37000.46
XOM57.051.84003.33
WFC48.091.01002.15
JNJ165.621.69001.03
FB346.583.37000.98
GE103.915.37005.45
JPM161.545.63003.61
Financial StrengthValueIndustryS&P 500US Markets
2.70
3.90
0.01
0.02
467.10
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
56.60
181.50
186.30
52.70
84.36
RevenueValueIndustryS&P 500US Markets
2.88B
116.58
5.80
5.45
Earnings HistoryEstimateReportedSurprise %
Q02 20211.903.5486.32
Q01 20212.505.21108.40
Q04 20203.104.0129.35
Q03 20201.853.0062.16
Q02 20201.301.6123.85
Q01 20201.401.9136.43
Q04 20192.462.32-5.69
Q03 20191.361.6118.38
Earnings Per EndEstimateRevision %Trend
9/2021 QR2.3012.75Positive
12/2021 QR3.157.88Positive
12/2021 FY14.2017.65Positive
12/2022 FY12.355.11Positive
Next Report Date4th Nov 2021
Estimated EPS Next Report2.30
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume56.84K
Shares Outstanding29.77M
Shares Float21.16M
Trades Count2.09K
Dollar Volume141.94M
Avg. Volume160.16K
Avg. Weekly Volume178.74K
Avg. Monthly Volume145.11K
Avg. Quarterly Volume122.25K

Bio-Rad Laboratories Inc. Class A (NYSE: BIO) stock closed at 785.64 per share at the end of the most recent trading day (a 0.02% change compared to the prior day closing price) with a volume of 94.43K shares and market capitalization of 23.80B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class A CEO is Norman Schwartz.

The one-year performance of Bio-Rad Laboratories Inc. Class A stock is 56.12%, while year-to-date (YTD) performance is 34.77%. BIO stock has a five-year performance of 386.95%. Its 52-week range is between 490.73 and 832.7, which gives BIO stock a 52-week price range ratio of 90.27%

Bio-Rad Laboratories Inc. Class A currently has a PE ratio of 5.90, a price-to-book (PB) ratio of 2.02, a price-to-sale (PS) ratio of 6.71, a price to cashflow ratio of 34.50, a PEG ratio of 2.32, a ROA of 31.39%, a ROC of 40.75% and a ROE of 41.80%. The company’s profit margin is 84.36%, its EBITDA margin is 186.30%, and its revenue ttm is $2.88 Billion , which makes it $116.57 revenue per share.

Of the last four earnings reports from Bio-Rad Laboratories Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.30 for the next earnings report. Bio-Rad Laboratories Inc. Class A’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class A is Strong Buy (1), with a target price of $843.33, which is +5.55% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class A stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Rad Laboratories Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Rad Laboratories Inc. Class A has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.18, ATR14 : 16.66, CCI20 : -93.53, Chaikin Money Flow : 0.15, MACD : 6.23, Money Flow Index : 52.61, ROC : -4.16, RSI : 50.04, STOCH (14,3) : 19.71, STOCH RSI : 0.16, UO : 53.06, Williams %R : -80.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class A in the last 12-months were: Ajit Ramalingam (Option Excercise at a value of $0), Andrew J. Last (Option Excercise at a value of $598 480), Andrew J. Last (Sold 2 000 shares of value $1 626 203 ), Annette Tumolo (Option Excercise at a value of $191 184), Annette Tumolo (Sold 1 800 shares of value $1 244 413 ), Dara Wright (Option Excercise at a value of $0), Ilan Daskal (Option Excercise at a value of $716 898), Ilan Daskal (Sold 3 110 shares of value $2 397 778 ), Michael Crowley (Option Excercise at a value of $418 680), Michael Crowley (Sold 3 374 shares of value $2 481 966 ), Norman Schwartz (Option Excercise at a value of $3 702 220), Timothy S. Ernst (Option Excercise at a value of $63 728), Timothy S. Ernst (Sold 1 446 shares of value $965 649 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Bio-Rad Laboratories Inc. Class A

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

CEO: Norman Schwartz

Telephone: +1 510 724-7000

Address: 1000 Alfred Nobel Drive, Hercules 94547, CA, US

Number of employees: 8 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

63%37%

Bearish Bullish

57%43%

News

Stocktwits